Drug intelligence / Profile preview

[89Zr]Zr-DFO-EGFRvIII

Development stage
Preclinical
Lead developer
Universidad de Santiago de Compostela
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
Administration
Intravenous
01

Overview

[89Zr]Zr-DFO-EGFRvIII is a preclinical-stage antibody-based radiopharmaceutical designed for immuno-positron emission tomography (immunoPET) imaging of glioblastoma (GBM). It consists of a monoclonal antibody targeting the epidermal growth factor receptor variant III (EGFRvIII) mutation, conjugated with the chelator deferoxamine (DFO) and radiolabeled with the positron-emitting isotope zirconium-89 (89Zr). Developed by researchers at the University of Santiago de Compostela and the Vall d'Hebron Institute of Oncology, this tracer is used to non-invasively assess and quantitatively map EGFRvIII expression in vivo, particularly in glioblastoma models, to aid in patient stratification for EGFRvIII-targeted therapies.

Other names
89Zr-DFO-EGFRvIII89Zr-DFO-anti-EGFRvIII[89Zr]Zr-DFO-anti-EGFRvIII
02

Identity

Drug type
Antibody-Based Therapeutics
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron EmittersGamma Emitters
03

Pharmacology

04

Development

IndicationHighest phaseStatus
glioblastoma, IDH-wildtypePreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Universidad de Santiago de CompostelaLead developer
07

Competitive landscape

Drugs on the same target
23
Drugs in the lead indication
709

Lead indication: glioblastoma, IDH-wildtype

Most advanced in the lead indication

  1. bevacizumabApproved
  2. carmustineApproved
  3. temozolomideApproved
  4. lacosamidePhase 4
  5. pembrolizumabPhase 4

Beyond the preview

Go deeper on [89Zr]Zr-DFO-EGFRvIII.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on [89Zr]Zr-DFO-EGFRvIII.

Work on [89Zr]Zr-DFO-EGFRvIII? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call